Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) reported that the USPTO issued a new U.S. Patent named as, “Pharmacological Treatment of Parkinson’s Disease.” It covers process for the administration of lead drug eltoprazine, in combination with levodopa, for the cure of Parkinson’s disease.
The achievement
Gerald E. Commissiong, the President and CEO said that they are extremely delighted with the issuance of the patent covering the process of eltoprazine in curing patients with Parkinson’s receiving L-DOPA. It also has the potential to treat patients who suffer from “L-DOPA” induced dyskinesia. The new patent will help Amarantus to expand its intellectual property assets for eltoprazine.
The Phase II b clinical trial has started with patient screening going well and now rapidly moving into the first randomization. The management anticipates the first patient to be randomized in the study shortly. Commencement of patient screening is a vital step forward taken to ramp up the trial process. The team believes that eltoprazine has immense potential to address a considerable unmet therapeutic need for patients suffering with Parkinson’s disease.”
The details
Amarantus is preparing to initiate Phase 2b clinical plan for the treatment of PD-LID, which is an abnormal uncontrolled, movement disorder. It is induced from prolonged levodopa-based treatment. PD-LID is seen in almost 60%-80% of Parkinson’s patients and is termed as one of the major problems associated with Parkinson’s treatment. This problem can be severely disabling and hampers quality of life by snatching the ability to carry out routine activities.
Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) has commenced a multi-center, Phase 2b study in patients with PD-LID. The study, which will have 60 subjects, is a double blind, dose range finding, four-way crossover and placebo controlled clinical study.
In last trading session, the stock price of Amarantus gained more than 11% to close the trading session at $5.22. The gains came at a share volume of 40,908 compared to average share volume of 22,275.
